The Spanish companies Biotools and 2B BlackBio have signed a global license agreement of products and transference of technology, in the fields of molecular diagnosis and personalized medicine with the Mexican pharmaceutics Silanes Laboratories.
This agreement will allow Silanes Laboratories to make and to commercialize diagnostic kits based on nucleic acid amplification technologies and stabilization of complex reaction mixtures (“Gelification”) patented by Biotools, and on the “accelerated high-sensitivity microsequencing patent” by 2B BlackBio, as well as to develop new products and systems based on the transferred technologies.
Silanes Laboratories have 68 years of experience in the pharmaceutical market and medical prescription.
In addition it invests 10% of its sales in research and development at national level, in countries like Spain and the United States, and also has a portfolio of 100 health products.
Silanes Laboratories is, in Mexico, the leading manufacturer of combined oral anti diabetics, manufacturing annually 1600 million tablets, taking care of million patients who live with diabetes mellitus type 2 in Mexico, South America, Central America and the Caribbean.
In the field of Biotechnology is an international leader in research, development, manufacture and marketing of Fabotherapics, protected by international patents, and it is the only company in Latin America obtaining an FDA approval for an innovating biotechnological product.